105 related articles for article (PubMed ID: 23073056)
21. Pulmonary toxicity of 5-fluoracil and oxaliplatin.
Ruiz-Casado A; García MD; Racionero MA
Clin Transl Oncol; 2006 Aug; 8(8):624. PubMed ID: 16952855
[No Abstract] [Full Text] [Related]
22. [FOLFOX-related hypersensitivity reactions: clinical presentation and management].
Yanai T; Iwasa S; Yamada Y
Nihon Rinsho; 2011 Apr; 69 Suppl 3():541-4. PubMed ID: 22214019
[No Abstract] [Full Text] [Related]
23. Oxaliplatin-induced thrombotic thrombocytopenic purpura: case report and literature review.
Niu J; Mims MP
J Clin Oncol; 2012 Nov; 30(31):e312-4. PubMed ID: 22987080
[No Abstract] [Full Text] [Related]
24. Fatal diffuse alveolar damage associated with oxaliplatin administration.
Watkins J; Slade JH; Phan A; Eng C; Weissferdt A; Overman MJ
Clin Colorectal Cancer; 2011 Sep; 10(3):198-202. PubMed ID: 21855043
[TBL] [Abstract][Full Text] [Related]
25. Oxaliplatin-induced immune mediated thrombocytopenia.
Beg MS; Komrokji RS; Ahmed K; Safa MM
Cancer Chemother Pharmacol; 2008 Oct; 62(5):925-7. PubMed ID: 18204841
[TBL] [Abstract][Full Text] [Related]
26. [Sinusoidal obstruction syndrome induced by FOLFOX adjuvant chemotherapy].
Chaput U; Coriat R; Terris B; Brezault C; Chaussade S
Gastroenterol Clin Biol; 2008 Dec; 32(12):992-4. PubMed ID: 19019605
[No Abstract] [Full Text] [Related]
27. [FOLFOX].
Mishima H; Ikenaga M; Tsujinaka T; Yasui M; Kashiwazaki M; Miyazaki M; Hirao M; Fujitani K; Nakamori S
Gan To Kagaku Ryoho; 2006 Jul; 33(7):911-4. PubMed ID: 16835479
[TBL] [Abstract][Full Text] [Related]
28. Adjuvant therapy for colorectal cancer: increasingly complex as patients age.
Sanoff HK; O'Neil BH
Oncology (Williston Park); 2009 Feb; 23(2):173-4. PubMed ID: 19323299
[No Abstract] [Full Text] [Related]
29. [Chemotherapy of colonic cancer].
Block S
Soins; 2010 Mar; (743):46. PubMed ID: 20423037
[No Abstract] [Full Text] [Related]
30. Oxaliplatin-induced hepatocellular injury and ototoxicity: a review of the literature and report of unusual side effects of a commonly used chemotherapeutic agent.
Vietor NO; George BJ
J Oncol Pharm Pract; 2012 Sep; 18(3):355-9. PubMed ID: 22333669
[TBL] [Abstract][Full Text] [Related]
31. [Reduction of oxaliplatin-related neurotoxicity by calcium and magnesium infusions].
Muto O; Ando H; Ono T; Itagaki H; Kobayashi Y; Onuki M; Akashi T; Tanaka Y; Hanaoka T
Gan To Kagaku Ryoho; 2007 Apr; 34(4):579-81. PubMed ID: 17431344
[TBL] [Abstract][Full Text] [Related]
32. [Report of two cases of hepatitis B virus reactivation in primary liver carcinoma patients treated with the FOLFOX chemotherapy regimen].
Wang F; Qin S; Hua H; Liu X; Qu W; Li P
Zhonghua Gan Zang Bing Za Zhi; 2014 Mar; 22(3):236-8. PubMed ID: 24919228
[No Abstract] [Full Text] [Related]
33. Modified FOLFOX-4 as first-line and salvage treatment in advanced gastric cancer.
Baek YH; Choi SR; Jang JS; Roh MH; Lee JH; Won JJ; Lee CM
Hepatogastroenterology; 2011; 58(105):251-6. PubMed ID: 21510324
[TBL] [Abstract][Full Text] [Related]
34. Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen.
André T; Bensmaine MA; Louvet C; François E; Lucas V; Desseigne F; Beerblock K; Bouché O; Carola E; Merrouche Y; Morvan F; Dupont-André G; de Gramont A
J Clin Oncol; 1999 Nov; 17(11):3560-8. PubMed ID: 10550155
[TBL] [Abstract][Full Text] [Related]
35. Paclitaxel, oxaliplatin, 5-fluorouracil and leucovorin combination chemotherapy in patients with recurrent or metastatic gastric cancer.
Lan YQ; Wu RP; Huang XB; Wang XL; Zhong DT; Huang CY; Song JT
Tumori; 2018; 104(1):22-29. PubMed ID: 28777427
[TBL] [Abstract][Full Text] [Related]
36. [Successful management using laparoscopic splenectomy for splenomegaly and thrombocytopenia caused by oxaliplatin-based chemotherapy for advanced rectal cancer].
Koike N; Ohshima Y; Takeuchi T; Arita S; Shinozaki E
Gan To Kagaku Ryoho; 2013 Jun; 40(6):815-7. PubMed ID: 23863666
[TBL] [Abstract][Full Text] [Related]
37. [Epiphora in a patient receiving FOLFOX therapy].
Yatsuda C; Niimi M; Ono Y; Uto N; Iwagami E; Tanaka E; Yamato M
Gan To Kagaku Ryoho; 2008 Nov; 35(11):1989-91. PubMed ID: 19011359
[TBL] [Abstract][Full Text] [Related]
38. Atypical cutaneous lymphoid hyperplasia induced by chemotherapy in a patient with advanced colon carcinoma.
Addeo R; Montella L; Baldi A; Cennamo G; Guarrasi R; Faiola V; Caraglia M; Del Prete S
Clin Colorectal Cancer; 2007 Nov; 6(10):728-30. PubMed ID: 18039427
[TBL] [Abstract][Full Text] [Related]
39. Fatal thrombocytopenia after oxaliplatin-based chemotherapy.
Shao YY; Hong RL
Anticancer Res; 2008; 28(5B):3115-7. PubMed ID: 19031966
[TBL] [Abstract][Full Text] [Related]
40. Oxaliplatin-induced immune hemolytic anemia: a case report and review of the literature.
Cobo F; De Celis G; Pereira A; Latorre X; Pujadas J; Albiol S
Anticancer Drugs; 2007 Sep; 18(8):973-6. PubMed ID: 17667605
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
